Journal
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Volume 39, Issue 9, Pages 1364-1371Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/03639045.2012.718784
Keywords
Pyridostigmine bromide; taste-masked; orally disintegrating tablets; Solid dispersions; central composite design; bioequivalence
Categories
Funding
- National Natural Science Foundation of China [30973645]
- Specialized Research Fund for the Doctoral Program of Higher Education [20095503120008]
- Chongqing Natural Science Foundation [CSTC 2012JJB10027]
- Chongqing Education Committee [KJ120321]
Ask authors/readers for more resources
The purpose of this study was to evaluate the taste masking potential of novel solid dispersions (SDs) using Eudragit (R) EPO as the excipient when incorporated into the orally disintegrating tablets (ODTs) for delivering a highly soluble drug with an extremely bitter taste. The pyridostigmine bromides (PB) SDs (PBSDs) were prepared by solvent evaporation-deposition method. The physicochemical properties of PBSDs were investigated by means of differential scanning calorimetry and Fourier transformed infrared spectroscopy. The dissolution test showed that only about 8% of PB was released from PBSDs in the simulated salivary fluid in 30 s. Therefore, PBSDs were considered taste-masked and selected for formulation of PBODTs. A central composite design was employed for process optimization. Multiple linear regression analysis for process optimization revealed that the optimal PBODTs were obtained, when the microcrystalline cellulose and crospovidone were 17.16 and 5.55 (%, w/w), respectively, and the average in vivo disintegration time was 25 s. The bitterness threshold of PB was examined by a sensory test, and the threshold value was set as 3 mg in each tablet. Taste evaluation of PBODTs in 18 volunteers revealed considerable taste masking with bitterness below the threshold value. PBODTs also revealed rapid drug release (around 99%, 2 min) in the simulated gastric fluid. The mean PB plasma concentration-time profiles of PBODTs and that of the commercial tablets were comparable, with closely similar pattern. Bioequivalence assessment results demonstrated that PBODTs and the commercial tablets were bioequivalent. In conclusion, PBODTs are prepared successfully, with taste masking and rapid disintegration in the oral cavity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available